Skip to main navigation Skip to search Skip to main content

Pharmacokinetic model of target-mediated disposition of thrombopoietin.

  • SUNY Buffalo

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Thrombopoietin, TPO, a 353 amino acid cytokine, is a primary regulator of platelet production that was cloned recently. A target-mediated (platelet receptors) pharmacokinetic model was developed to characterize the disposition of TPO. Receptor-mediated endocytosis was assigned as the major elimination pathway in the model. A nonspecific binding compartment was also incorporated into the model. TPO concentration vs time profiles from a published phase 1 and 2 clinical trial were used to apply this model. Noncompartmental analysis demonstrated that TPO exhibits nonlinear kinetics. The proposed model captured the concentration-time profiles relatively well. The first-order internalization rate constant was estimated as 0.1 h(-1). The endogenous binding capacity was estimated as 164.0 pM. The second-order binding association constant (k(on)) was 0.055 h(-1).pM(-1) and the first-order dissociation constant (k(off)) was estimated as 2.5 h(-1), rendering the equilibrium dissociation constant K(d) as 45.5 pM. This model may be relevant to other therapeutic agents with receptor-mediated endocytotic disposition.

Original languageEnglish
Pages (from-to)E9
JournalAAPS PharmSci
Volume6
Issue number1
StatePublished - Mar 9 2004

Fingerprint

Dive into the research topics of 'Pharmacokinetic model of target-mediated disposition of thrombopoietin.'. Together they form a unique fingerprint.

Cite this